We aim to develop the next generations of subtype-specific anti-senescence compounds to restore tissue homeostasis

Cleara’s expertise lies in understanding the molecular and biological pathways that underlie these pathological phenotypes to exploit their weak spots for safe and selective clearance

Cleara is a private, Netherlands-based biotech company, tied with the University Medical Center Utrecht. Our scientific founders discovered that senescent cells impair tissue function and promote cancer metastases in mice (Cell, 2017; Cancer Discovery, 2016). Since then, we identified that what is called senescence is actually a collection of different phenotypes.

Cleara set up a platform that utilizes knowledge to design and optimize compounds against specific subtypes of senescence, thereby allowing for precise elimination of these in respective diseases.  We do not focus on approaches to try to kill all senescent cells but develop specific and safe compounds against unique subtypes. Key to our approach is our D-amino acid peptide development pipeline (see programs tab for more info). Our aim is to employ these in precision medicine against specific chronic diseases identified using our biomarkers of companion diagnostics:

Our lead program is especially centered around targeting “scarred” senescent and cancer cells, which are elevated in persistent damage and biomarkers as active p53 and PML (see Focus tab for more details). Cleara’s goal is to progress our scarring-specific FOXO4/p53 peptides into clinical development with a clear initial focus on p53-driven cancer metastases: